Synaptogenix Inc. Common Stock is a biopharmaceutical company focused on developing therapeutics for Alzheimer’s disease and other neurodegenerative disorders. Their innovative approach aims to target synaptic dysfunction, a key factor in the progression of these conditions. With promising preclinical results, Synaptogenix is poised to make a significant impact in the field of neurology.
- Latest
- Trending
